Form D · Pharmaceuticals
STAQ Pharma, Inc.
Denver, CO · CIK 0001722397
Offering snapshot reported Sep 16, 2024 · SEC filing
- Reported sold
- $11.4M Offering amount: $30M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Sep 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 16, 2024 | Initial | $11,400,001 | No comparison | 8 | SEC filing |
| Jun 21, 2023 | Amendment | $10,121,691 | $2,110,026vs Apr 28, 2023 | 17 | SEC filing |
| Apr 28, 2023 | Initial | $8,011,665 | No comparison | 10 | SEC filing |
| Dec 23, 2021 | Amendment | $30,262,815 | $27,262,815vs Jan 5, 2021 | 19 | SEC filing |
| Mar 31, 2021 | Amendment | $9,000,000 | $1,214,350vs Apr 7, 2020 | 23 | SEC filing |
| Jan 5, 2021 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Apr 7, 2020 | Amendment | $7,785,650 | $5,785,650vs May 3, 2019 | 20 | SEC filing |
| Feb 25, 2020 | Amendment | $6,375,546 | $4,375,546vs May 3, 2019 | 20 | SEC filing |
| May 3, 2019 | Initial | $2,000,000 | No comparison | 17 | SEC filing |
| Apr 3, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 21, 2017 | Initial | $625,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524144
Source: Form D, filed Sep 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph W Bagan | Director, Executive |
| Stephen Davis | Director |
| Abram Gordon | Director |
| Brad Hauert | Director |
| Scott Hawig | Director |
| Jeffrey L Hval | Director, Executive |
| Paul Jenny | Director |
| Chet Kaczor | Director |
| Carol Lewis | Director |
| Donna Lynne | Director |
| Jerrod Milton | Director |
| Dan Seff | Director |
| Mark M Spiecker | Director, Executive |
| Steven Summer | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
14135 E. 42 Nd Ave. Unit 50
Denver, CO, 80239
Denver, CO, 80239